Xuan Zhou

Xuan Zhou

Auto-generated profile, based on publicly available information

Xuan Zhou

Oligonucleotide Process Development

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2016 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
XZXuan Zhou
Xuan Zhou
CCCen Chen
Cen Chen
XYXiaolan Ye
Xiaolan Ye
FSFenyun Song
Fenyun Song
GFGuorong Fan
Guorong Fan
FWFuhai Wu
Fuhai Wu

20 September 2023 in The Analyst
Verified
Journal Article
Open access
PDF file
ZLZifan Li
Zifan Li
FTFei Tong
Fei Tong
LXLi Xiao
Li Xiao
NLNicholas R. Larson
Nicholas R. Larson
XZXuan Zhou
Xuan Zhou
GBGeorge M. Bou-Assaf
George M. Bou-Assaf
NP1 digestion coupled with UHPLC-HRMS can provide valuable information on stereochemical comparability between phosphorothioate oligonucleotides by examining digestion fragments.

6 August 2021 in Research Square
Verified
Preprint
Open access
PDF file
XSXianglin Shi
Xianglin Shi
XZXuan Zhou
Xuan Zhou
WYWuming Yan
Wuming Yan
WKWilliam Kiesman
William Kiesman
YFYannick Fillon
Yannick Fillon
RGRobert Gronke
Robert Gronke
The recent explosive growth in the number of oligonucleotide clinical development programs and drug approvals underscores their ability to treat diseases via mRNA regulation. Currently, solid-supported synthesis is limited to ≤ 5 kg (~ 1 mole) batch sizes and the feasibility of liquid-phase syntheses to supply materials of sufficient purity and amount for clinical trials has not been proven. Herein we describe the first convergent synthesis of a full-length 18-mer mixed backbone (PO/PS) 2’-MOE gapmer oligonucleotide by the phosphoramidite approach suitable for use in clinical trials. Techniques described to control impurities during its synthesis can be implemented in common active pharmaceutical ingredient (API) manufacturing facilities and should enable a >10-fold increase in production batch scaling.

21 October 2024 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
XZXuan Zhou
Xuan Zhou
YFYannick Fillon
Yannick Fillon
XSXianglin Shi
Xianglin Shi
FAFiroz Antia
Firoz Antia
XZXiao Zhou
Xiao Zhou
ALAngela Lin
Angela Lin

1 April 2024 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
XZXuan Zhou
Xuan Zhou
XSXianglin Shi
Xianglin Shi
YFYannick Fillon
Yannick Fillon
FAFiroz Antia
Firoz Antia
TPThomas Pickel
Thomas Pickel
JZJiabao Zhang
Jiabao Zhang
Oligonucleotides have emerged as valuable new therapeutics. Presently, oligonucleotide manufacturing consists in a series of stepwise additions until the full-length product is obtained. Deprotection of the phosphorus backbone before cleavage and deprotection (C&D) by ammonolysis is necessary to control the 3-(2-cyanoethyl) thymidine (CNET) impurity. In this study, we demonstrate that the use of piperazine as a scavenger of acrylonitrile allows phosphorus deprotection and C&D to be combined in a single step. This reduces solvent consumption, processing time, and CNET levels. Additionally, we showed that substitution of piperazine for triethylamine in the phosphorus deprotection step of supported-synthesis leads to reduced reaction times and lower levels of CNET impurities.